Corporate Profile

Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Our proprietary mRNA therapeutic platform (MRTTM) is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. We believe that our MRTTM platform is applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease. Our lead program is being developed as treatment for cystic fibrosis (CF) and is currently in a Phase 1/2 clinical trial in patients with CF. Beyond CF, the primary focus of our research efforts is the evaluation of targets in additional pulmonary diseases utilizing our proprietary lung delivery platform and we have early-stage discovery efforts in additional disease areas.  Additionally, the MRTTM platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as oncology and infectious disease; in the case of the latter, we have a collaboration with Sanofi Pasteur to develop novel mRNA vaccines for all infectious disease pathogens, including SARS-CoV-2, the novel coronavirus responsible for the disease known as COVID-19.

2020 Shareholder Letter
Translate Bio Fact Sheet

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.